Drug Pricing

Drug Pricing

Bill Smith – Rationing Medicine

Bill Smith of the Pioneer Institute in Massachusetts joins Wayne and Tim to discuss his important new book “Rationing Medicine”, which focuses on an obscure economic concept called QALYs – or quality adjusted life years. 


New COVID-19 research is troubling

Gov’t Undermines Search for Heart Disease Treatments

New research into COVID-19 has revealed some troubling findings. Even mild cases can lead to lasting heart complications. Comparing test data collected before and after a group of patients in their mid-30s contracted mild cases of COVID, researchers noticed an increase in arterial stiffness and cardiovascular inflammation. That means they may face “a widespread …


Read latest on drug pricing

The Continuing Danger From Progressive’s Faulty Excess Profit Allegations

Sen. Bernie Sanders (D-Vermont) and Rep. Alexandria Ocasio-Cortez (D-New York) continuously confirm Alexander Pope’s famous maxim about a little bit of knowledge. It truly is a dangerous thing, especially in the hands of politicians. During a May 11th meeting of the Senate Health, Education, Labor and Pensions (HELP) committee, Sen. …


Today's commentary on pharmaceutical benefit managers

Will Senate Hearing Expose PBMs’ Unscrupulous Drug Pricing Tactics?

Today , Sen. Bernie Sanders, I-Vt., will haul executives from three insulin manufacturers and three pharmacy benefit managers before the Senate Health, Education, Labor and Pensions Committee for a hearing on “the need to make insulin affordable for all Americans.” Sen. Sanders is sure to call the pharmaceutical executives — …


Thank the IRA for Cuts to Critical Drug Research

President Biden’s Inflation Reduction Act is just eight months old. It hasn’t yet slayed inflation. But it’s already gutting drug research and development. The law gives Medicare the power to impose price controls on certain prescription drugs for the first time. By September, federal officials will select the first 10 …


Small-Molecule Price Controls Are A Big Mistake

The Biden administration is in the midst of setting the terms for its program of price controls on prescription drugs dispensed through Medicare. The first 10 medicines subject to the price caps will be selected by the end of this year. That prospect is already chilling investment in drug research, particularly …

Drug Innovation

Wayne Winegarden on NTD News to Discuss Congress Pushing Back on Pharmaceutical Benefit Managers

Congress is beginning to push back on pharmaceutical benefit managers (PBMs). PRI’s Wayne Winegarden tells NTD News that a large problem lies in the lack of transparency in the drug pricing system. Reforming the PBM system could reduce costs for patients. Click to watch the interview on NTD News.


Price controls in Medicare will kill new cures

President Biden just released his budget plan for the next fiscal year. It purports to extend Medicare’s solvency by decades and reassure the millions of Americans who rely on the program. But once they realize his approach will grind drug research to a halt, perhaps they’ll come to a different conclusion. The …


Read about the middlemen in healthcare

Pharmacy benefit managers are picking patients’ pockets

Pharmacy benefit managers are in the congressional hot seat. Last Thursday, the Senate Finance Committee held a hearing examining the middlemen’s impact on patients. Earlier in March, the House Committee on Oversight and Accountability launched an investigation into PBM tactics that are “harming patient care and increasing costs for consumers.” …


A Bipartisan Regulatory Reform Opportunity: 340B

Despite the rancor, there are many bipartisan opportunities for the divided 118th Congress. Near the top of the to-do list should be reforming the well-intentioned, but poorly designed, 340B drug discount program. 340B enables qualifying institutions to purchase medicines from manufacturers at steep discounts, generally between 25% and 50% off list …

Scroll to Top